HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative from Patient Medical Records in The Gulf Cooperation Council

Trial Identifier: D133FR00197
Sponsor: AstraZeneca
Start Date: March 2024
Primary Completion Date: September 2024
Study Completion Date: September 2024
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Kuwait, Kuwait Kuwait, Kuwait
Qatar, Qatar Doha, Qatar, Qatar
Saudi Arabia, Saudi Arabia Makkah, Saudi Arabia, Saudi Arabia
Saudi Arabia, Saudi Arabia Riyadh, Saudi Arabia, Saudi Arabia
United Arab Emirates, United Arab Emirates Abu Dhabi, United Arab Emirates, United Arab Emirates
United Arab Emirates, United Arab Emirates Al Ain, United Arab Emirates, United Arab Emirates
United Arab Emirates, United Arab Emirates Dubai, United Arab Emirates, United Arab Emirates